CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $9.18B, above the global median of $1.15B
- PositionOperating margin is 74.4%, higher than 95% of its Biotechnology peers (median -23.8%)
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
9.18BUSDvs all stocks (USD)
Trailing P/E
136.40xvs Biotechnology peers
Revenue (TTM)
281.99MUSDvs all stocks (USD)
Profit Margin
29.40%vs Biotechnology peers
Beta
1.79xvs all stocks
52-Week Change
117.77%vs all stocks
Market Capitalization
9.18BUSDvs all stocks (USD)
Enterprise Value
8.41BUSDvs all stocks (USD)
Trailing P/E
136.40xvs Biotechnology peers
Forward P/E
-712.33xvs Biotechnology peers
PEG Ratio
-0.2484xvs Biotechnology peers
Price to Sales (TTM)
32.55xvs Biotechnology peers
Price to Book (MRQ)
10.90xvs Biotechnology peers
Enterprise to Revenue
29.81xvs Biotechnology peers
Enterprise to EBITDA
140.38xvs Biotechnology peers
Profit Margin
29.40%vs Biotechnology peers
Operating Margin
74.37%vs Biotechnology peers
Return on Assets (TTM)
4.55%vs Biotechnology peers
Return on Equity (TTM)
10.98%vs Biotechnology peers
Revenue (TTM)
281.99MUSDvs all stocks (USD)
Revenue per Share (TTM)
4.36USDUpdated Sep 28, 2026Quarterly Revenue Growth
3749.20%vs Biotechnology peers
Gross Profit (TTM)
281.99MUSDvs all stocks (USD)
EBITDA (TTM)
59.88MUSDvs all stocks (USD)
Net Income (TTM)
82.91MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
3749.17%vs Biotechnology peers
Operating Cash Flow (TTM)
131.20MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
96.15MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
46.02MUSDFY2025 · Dec 31, 2025Operating Income
-158.13MUSDvs all stocks (USD)
Pre-tax Income
-129.31MUSDFY2025 · Dec 31, 2025Income Tax Expense
838.00KUSDFY2025 · Dec 31, 2025Net Income
-130.15MUSDFY2025 · Dec 31, 2025EBIT
-158.13MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-156.85MUSDFY2025 · Dec 31, 2025Research & Development
159.29MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
44.85MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
28.79MUSDFY2025 · Dec 31, 2025EPS (Basic)
-2.05USDFY2025 · Dec 31, 2025EPS (Diluted)
-2.05USDFY2025 · Dec 31, 2025Basic Shares Outstanding
63.57MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
63.57MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-130.15MUSDFY2025 · Dec 31, 2025Operating Cash Flow
65.37MUSDFY2025 · Dec 31, 2025Free Cash Flow
63.78MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
128.68MUSDFY2025 · Dec 31, 2025Interest Paid
3.69MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-130.15MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
1.28MUSDFY2025 · Dec 31, 2025Stock-based Compensation
45.97MUSDFY2025 · Dec 31, 2025Other Non-cash Items
1.58MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
164.88MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
3.72MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-21.92MUSDFY2025 · Dec 31, 2025Capital Expenditures
-1.59MUSDFY2025 · Dec 31, 2025Purchase of Investments
-546.59MUSDFY2025 · Dec 31, 2025Sale of Investments
498.84MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-49.33MUSDFY2025 · Dec 31, 2025Other Financing Charges
-479.00KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-479.00KUSDFY2025 · Dec 31, 2025Shares Outstanding
64.67MSharesUpdated Sep 28, 2026Float Shares
52.89MSharesUpdated Sep 28, 2026Shares Short
8.14MSharesUpdated Sep 28, 2026Short Ratio
15.45daysvs all stocks
Short % of Shares Outstanding
14.62%vs all stocks
% Held by Insiders
0.71%vs all stocks
% Held by Institutions
119.61%vs all stocks
Total Cash (MRQ)
782.58MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
12.09USDUpdated Sep 28, 2026Total Debt (MRQ)
9.22MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0109xvs Biotechnology peers
Current Ratio (MRQ)
21.71xvs Biotechnology peers
Book Value per Share (MRQ)
13.01USDUpdated Sep 28, 2026Total Assets
668.19MUSDvs all stocks (USD)
Total Current Assets
577.57MUSDFY2025 · Dec 31, 2025Total Liabilities
53.48MUSDFY2025 · Dec 31, 2025Total Non-current Assets
90.61MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
8.04MUSDFY2025 · Dec 31, 2025Total Current Liabilities
45.44MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
128.39MUSDFY2025 · Dec 31, 2025Other Short-term Investments
438.97MUSDFY2025 · Dec 31, 2025Accounts Payable
5.34MUSDFY2025 · Dec 31, 2025Short-term Debt
2.28MUSDFY2025 · Dec 31, 2025Deferred Revenue
9.55MUSDFY2025 · Dec 31, 2025Long-term Debt
8.04MUSDFY2025 · Dec 31, 2025Common Stock (Book)
1.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-470.67MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
614.71MUSDvs all stocks (USD)
52-Week Low
62.24USDUpdated Sep 28, 202652-Week High
160.81USDUpdated Sep 28, 202652-Week Change
117.77%vs all stocks
Beta
1.79xvs all stocks
50-Day MA
144.60USDUpdated Sep 28, 2026200-Day MA
110.03USDUpdated Sep 28, 2026Avg 10-Day Volume
808.86KSharesUpdated Sep 28, 2026Avg 30-Day Volume
611.18KSharesUpdated Sep 28, 2026Diluted EPS (TTM)
1.04USDUpdated Sep 28, 2026Other Income / Expense
27.00KUSDFY2025 · Dec 31, 20252 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Cash-Flow Ratios Elevated
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
Is this company growing?
Diagnostic
High R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Heavy R&D and stock pay, with the share count growing across six years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is 74.4%, higher than 95% of its Biotechnology peers (median -23.8%)Significant
Operating margin: 0.74Industry median: -0.24Industry P95: 0.38Peers compared: 184
P/E ratio is 136.4×, higher than 95% of its Biotechnology peers (median 33.93×)Significant
P/E ratio: 136.404Industry median: 33.93Industry P95: 134.356Peers compared: 184
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $9.18B, above the global median of $1.15BNotable
Market cap (USD): 9,179,517,310Global Median: 1,150,342,212.262
Levered free cash flow is $96.15M, above the global median of $18.98MNotable
Levered free cash flow (USD): 96,145,752Global Median: 18,979,762.15
Companies that share the same coordination system — how they create, deliver, or capture value.
Kymera Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Glaukos Corporation
Tier 1ProductionApproval-Gated PipelineRule
Arrowhead Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Fosun Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Crinetics Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Aurobindo Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Cytokinetics, Incorporated
Tier 1ProductionApproval-Gated PipelineRuleRisk
ImmunityBio, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Masimo Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow
Insulet Corporation
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
ASTERA LABS INC COMMON STOCK (Ticker: 1ALAB)
2 interpretationsCash-Flow Ratios ElevatedHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Delcath Systems Inc.
2 interpretationsCash-Flow Ratios ElevatedHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Spire Global Inc.
2 interpretationsCash-Flow Ratios ElevatedHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC